Dabigatran Etexilate
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
- Dabigatran Etexilate
- Dabigatran Etexilate: From Thromboembolic Disease Prevention to Sclerosing Cholangitis
Dabigatran Etexilate: From Thromboembolic Disease Prevention to Sclerosing Cholangitis
One-Sentence Summary
Dabigatran etexilate is the oral prodrug of dabigatran, a direct thrombin (Factor IIa) inhibitor used to prevent and treat thromboembolic disease; detailed original-indication data was not present in this evidence pack, so this characterisation draws on general drug-class knowledge rather than the source data. The TxGNN model predicts it may be effective for Sclerosing Cholangitis, but this is currently supported by 0 clinical trials and only 1 tangentially related publication, with no direct evidence linking the drug’s mechanism to this disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the available data (general drug-class knowledge: prevention/treatment of thromboembolic disease) |
| Predicted New Indication | Sclerosing Cholangitis |
| TxGNN Prediction Score | 99.82% |
| Evidence Level | L5 |
| UK Market Status | Not marketed (per source data — total authorisations on record: 0) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack. Based on general knowledge, dabigatran etexilate is a prodrug that is converted to dabigatran, a direct, reversible inhibitor of thrombin (Factor IIa), used to reduce thrombus formation in conditions such as stroke prevention in atrial fibrillation and venous thromboembolism.
Sclerosing cholangitis is a chronic, immune-mediated/inflammatory fibrosing disease of the bile ducts. There is no established pathophysiological link between thrombin inhibition and biliary fibrosis or cholestatic inflammation, and the evidence pack’s own repurposing rationale explicitly states that no known mechanistic connection exists between the two.
The single literature record retrieved (PMID 36906733) does not support the prediction directly: it is a pharmacokinetic drug-drug interaction methodology paper for cilofexor (an FXR agonist being developed for sclerosing cholangitis), in which dabigatran is mentioned only as a probe substrate for CYP450/transporter interaction testing — not as a treatment being evaluated for this disease. On the evidence currently available, this prediction should be regarded as a model-driven signal only, without mechanistic or clinical corroboration.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36906733 | 2023 | Review (PK/DDI methodology) | Clinical Pharmacokinetics | Evaluates drug-drug interaction potential of cilofexor (an FXR agonist in development for sclerosing cholangitis/NASH); dabigatran is referenced only as a probe substrate for CYP450/transporter interaction testing, not as a treatment for the disease itself |
UK Market Information
No MHRA marketing authorisation records for dabigatran etexilate were identified in the data source used for this evaluation (0 authorisations on record). This should be independently verified against the current MHRA product register and the electronic Medicines Compendium (eMC), as this status may reflect a data-source limitation rather than confirmed non-marketing.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale:
- No clinical trials and no directly relevant literature support dabigatran etexilate for sclerosing cholangitis; the single retrieved publication does not evaluate the drug for this indication. The evidence pack’s own mechanistic assessment finds no known biological link between thrombin inhibition and biliary fibrosis, so the high TxGNN score is not currently corroborated by independent evidence.
To proceed, the following is needed:
- Confirmation of UK marketing authorisation status directly from the MHRA/eMC register
- Original indication and MOA data for dabigatran etexilate (currently flagged as data gaps in this evidence pack)
- Preclinical or mechanistic studies specifically testing a rationale for thrombin inhibition in cholangitis/biliary fibrosis before further evaluation is warranted
- SmPC-derived warnings, contraindications and drug interaction data for a formal safety assessment (S1 stage)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.